Safety Profile
Known Safety Concerns
- Cardiovascular events -- associated with pharmaceutical form (ranelate)
- Interferes with DEXA bone density measurement
- Renal accumulation with chronic use
- DRESS syndrome (pharmaceutical form)
- Benefit in supplement form unproven
Contraindications
- Cardiovascular events -- associated with pharmaceutical form (ranelate)
- Interferes with DEXA bone density measurement
Interactions
Information not yet available for this ingredient profile.
Evidence and Scientific Findings
Ingredient Overview
Strontium supplements are marketed for bone density. Pharmaceutical strontium ranelate was severely restricted in Europe due to increased cardiovascular events and rare severe skin reactions (DRESS syndrome). Supplement forms (strontium citrate) have not been proven to have the same cardiovascular risks but benefit versus risk is unestablished. Strontium interferes with DXA bone density measurements.
Biological and Chemical Classification
- Scientific Name
- Strontium (various salts: ranelate, citrate, chloride)
Mechanism of Action
Information not yet available for this ingredient profile.
Clinical Evidence of Effectiveness
Information not yet available for this ingredient profile.
Pharmacokinetics
Information not yet available for this ingredient profile.
Recommended Dosage
Information not yet available for this ingredient profile.
SETI — Scientific Evidence Transparency Index
Executive Summary — Ingredient Assessment
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or RCT)
- Main clinical benefit observed: Mineral
- Evidence consistency: High consistency across studies (100%)
- Cardiovascular events -- associated with pharmaceutical form (ranelate)
- Interferes with DEXA bone density measurement
- Renal accumulation with chronic use
- DRESS syndrome (pharmaceutical form)
- Benefit in supplement form unproven
The available scientific evidence for Strontium indicates notable safety signals that warrant caution. Use should be considered carefully and monitored, particularly in sensitive populations or alongside other medications.
Total SETI Score
High risk| Evidence quality | 10/40 |
| Evidence consistency | 20/20 |
| Safety signals | 0/20 |
| Study recency | 10/10 |
| Evidence transparency | 10/10 |
Evidence Summary
- 10 studies reviewed
- 0 high-quality studies (meta-analysis or systematic review)
- 0 studies identified benefits or no safety concern (GREEN)
- 10 studies reported limited or advisory safety evidence (YELLOW)
Evidence Policy
Only peer-reviewed scientific literature indexed in PubMed or comparable databases is included in this evaluation. Commercial websites, blogs, and marketing materials are excluded. All references include direct traceable links to source documents.
Last updated: 25 მარ 2026, 22:14
Evidence Distribution
-
Observational / other LOW evidence YELLOWF/N co-doped SrTiO(3) for enhanced photocatalytic water oxidation under visible light. ↗Yan Y et al.. F/N co-doped SrTiO(3) for enhanced photocatalytic water oxidation under visible light.. Chem Commun (Camb). 2026. PMID:41879617.PMID 41879617 ↗Journal Chem Commun (Camb)Year 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41879617/
-
Observational / other LOW evidence YELLOWFabrication techniques and biomedical applications of strontium-based nanofibers. ↗Mahmoud ED et al.. Fabrication techniques and biomedical applications of strontium-based nanofibers.. J Nanobiotechnology. 2026. PMID:41877148.PMID 41877148 ↗Journal J NanobiotechnologyYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41877148/
-
Observational / other LOW evidence YELLOWDepth of nutrient uptake by deep-rooted plants is regulated by water availability. ↗Li L et al.. Depth of nutrient uptake by deep-rooted plants is regulated by water availability.. Proc Natl Acad Sci U S A. 2026. PMID:41875151.PMID 41875151 ↗Journal Proc Natl Acad Sci U S AYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41875151/
-
Observational / other LOW evidence YELLOWIntegrated ore classification using stand-alone and hybridised machine learning algorithms. ↗Gholami Vijouyeh A et al.. Integrated ore classification using stand-alone and hybridised machine learning algorithms.. Sci Rep. 2026. PMID:41872354.PMID 41872354 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41872354/
-
Observational / other LOW evidence YELLOWStrontium chelate with Achyranthes bidentata polysaccharide as a carrier promotes bone regeneration through mediating the gut-liver-bone axis in TD chickens. ↗Ding WL et al.. Strontium chelate with Achyranthes bidentata polysaccharide as a carrier promotes bone regeneration through mediating the gut-liver-bone axis in TD chickens.. Phytomedicine. 2026. PMID:41861682.PMID 41861682 ↗Journal PhytomedicineYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41861682/
-
Observational / other LOW evidence YELLOWEvidence of a marine larval stage in coastrange sculpin Cottus aleuticus from a small coastal stream in California, USA, based on otolith… ↗Rundio DE et al.. Evidence of a marine larval stage in coastrange sculpin Cottus aleuticus from a small coastal stream in California, USA, based on otolith strontium isotopes.. J Fish Biol. 2026. PMID:41853981.PMID 41853981 ↗Journal J Fish BiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41853981/
-
Observational / other LOW evidence YELLOWLocal agricultural transition, crisis and migration in the Southern Andes. ↗Barberena R et al.. Local agricultural transition, crisis and migration in the Southern Andes.. Nature. 2026. PMID:41851452.PMID 41851452 ↗Journal NatureYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41851452/
-
Observational / other LOW evidence YELLOWFabrication and characterization of poly methyl methacrylate (PMMA) matrix modified with strontium nano-rods. ↗Megahed ON et al.. Fabrication and characterization of poly methyl methacrylate (PMMA) matrix modified with strontium nano-rods.. Sci Rep. 2026. PMID:41851219.PMID 41851219 ↗Journal Sci RepYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41851219/
-
Observational / other LOW evidence YELLOWThe missing code in osseointegration: A genome-wide review of RNA sequencing in implant integration. ↗Komatsu K et al.. The missing code in osseointegration: A genome-wide review of RNA sequencing in implant integration.. J Prosthodont Res. 2026. PMID:41850867.PMID 41850867 ↗Journal J Prosthodont ResYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41850867/
-
Observational / other LOW evidence YELLOWAssociations of mid-childhood per- and polyfluoroalkyl substances and early childhood metals with mid-childhood antibody titers. ↗Smith A et al.. Associations of mid-childhood per- and polyfluoroalkyl substances and early childhood metals with mid-childhood antibody titers.. Environ Epidemiol. 2026. PMID:41847597.PMID 41847597 ↗Journal Environ EpidemiolYear 2026Study type Observational / otherEvidence strength LOW evidencePubMed link https://pubmed.ncbi.nlm.nih.gov/41847597/
Score Transparency
0 of 10 approved references (score saturates at 10). More peer-reviewed studies = stronger evidence base.
Method: Q = number of approved references ÷ 10 (capped at 1.0)
Limited — mostly case reports or animal studies
Method: L = mean study-level weight across approved references. Level 1 (meta-analysis / systematic review) = 1.0; Level 2 (RCT) = 0.8; Level 3 (cohort/case-control) = 0.6; Level 4 (case report) = 0.4; Level 5 (animal / in-vitro) = 0.2.
Mixed or neutral — roughly equal benefit and risk signals
Method: D = (sum of risk-scored references − sum of benefit-scored references) ÷ total evidence score, then scaled from [−1, 1] to [0, 1]. 0.0 = pure benefit; 0.5 = neutral; 1.0 = pure risk.
One or more monitoring-level safety signals active
Method: S = 0.5 (neutral baseline) + sum of active signal severity deltas ÷ 10. Severity deltas: Critical = +2.0, High = +1.5, Moderate = +1.0, Low = +0.5. Capped at 1.0.
Final GIRI Score for Strontium. Risk level thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
Full methodology & data sources
The GIRI Score is computed entirely from structured data — no editorial scoring or subjective weighting is applied at any step.
- References: Only approved references are counted. Each reference is assigned an evidence level (L1–L5) and a direction (risk / neutral / benefit) by the reference manager or AI classifier.
- Safety Signals: Sourced from regulatory agencies (FDA, EMA, Health Canada, TGA, and others) and pharmacovigilance databases. Only active signals count toward the score.
- Formula version: GIRI Score v3.7.0 — Q × L × D × S × 10.
- Limitations: The score reflects published evidence and recorded signals as of the last update date. It is not a clinical risk assessment and should not replace advice from a qualified healthcare professional.
Risk Level Classification
Based on available regulatory signals and scientific evidence, this ingredient presents a high safety concern. Its use in dietary supplements is associated with documented adverse events.
0–3.0
3.0–5.5
5.5–7.5
7.5–10
The score pin shows exactly where this ingredient falls on the fixed risk scale.
What drove the High classification for Strontium
A score of 6.0 places this ingredient in the High band. Thresholds: Low 0–3.0 · Moderate 3.0–5.5 · High 5.5–7.5 · Critical 7.5–10.
0 approved references.
Limited — mostly case reports or animal studies (Level 4–5).
Neutral or mixed — benefit and risk signals roughly balanced.
No active signals — S component is at neutral baseline (0.5), contributing no extra risk weight.
No major regulatory restrictions or advisories recorded across monitored jurisdictions (FDA, EMA, Health Canada, TGA, and others).
How are the Low / Moderate / High / Critical thresholds defined?
The four risk levels are fixed score bands. A score is assigned to exactly one level based on where it falls:
| Level | Score | Meaning |
|---|---|---|
| LOW | 0.0 – 2.9 | Sparse or predominantly beneficial evidence. No active safety alerts. |
| MODERATE | 3.0 – 5.4 | Mixed signals — some risk alongside benefit. Caution at high doses or in sensitive groups. |
| HIGH | 5.5 – 7.4 | Multiple studies or regulatory alerts documenting adverse effects. Professional oversight recommended. |
| CRITICAL | 7.5 – 10 | Regulatory restrictions in one or more major jurisdictions. Serious documented harm. Avoid without specialist supervision. |
Thresholds are fixed constants (GIRI_Score_Utils::LEVEL_THRESHOLDS). They do not change per ingredient and are never subject to editorial adjustment.